CDP 860

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCDP 860
Drug Alias Nameanti-platelet derived growth factor beta receptor antibodyanti-PDGF beta receptor antibodyCDP-860
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionPlatelet-derived growth factor inhibitors
TargetsPlatelet-derived growth factor
Therapy Area/IndicationsCoronary Restenosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelltechBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNektar TherapeuticsCelltechBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsCoronary Restenosis

Other Information

ATC CodeN/A
Related LinksN/A